Asthma Clinical Trial
Official title:
Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer
The investigators will study the use of a home-based spirometer (Spirobank Smart spirometer) that connects to a smartphone app (VitalFlo) in teenagers with persistent asthma to determine if clinically significant changes in lung function detected by the spirometer are associated with patient-reported asthma symptoms.
Asthma is a common chronic illness and significant expense to our healthcare system. Asthma
affects nearly 25 million Americans, including 10% of U.S. adolescents. Teenagers are one of
the most difficult groups to engage in self-management of chronic health problems like asthma
and are at greater risk of poorly controlled asthma compared to younger children. Up to 80%
of children with asthma are non-adherent to their controller medications, often due to lack
of parent or child-perceived need or beneficial effects of these medications. Adolescents may
have a higher threshold for initiating rescue treatment due to the perceived normalcy of
asthma symptoms and frequently under-report symptoms to parents and healthcare providers.
Poor perception of asthma symptoms leads to overestimation of asthma control. Defining well
controlled versus poorly controlled asthma is highly dependent on self-reported asthma
symptoms. Up to half of patients with severe asthma symptoms report well controlled asthma.
Many have low expectations of asthma control and have adapted to the disease so much so that
they no longer perceive their limitations. Inaccurate self-reported data can be problematic
in studies evaluating the impact of environmental factors or the efficacy of asthma
treatments. An objective measure of asthma impairment is pulmonary function testing performed
by spirometry. Ready access to a conventional spirometer is not always realistic in clinical
care or research settings. The investigators propose integrating technology-based tools that
leverage on the high rates of smartphone use among youth to identify early signs of
deteriorating asthma control.
The Spirobank smart spirometer is a compact, portable, home-based spirometer approximately
the size of an inhaler that pairs with a smartphone app called VitalFlo. The device uses an
energy conserving turbine. Exhaled air flow causes the turbine to rotate, generating a
voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced
expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first
second. The device prompts the user to perform a minimum of three expiratory maneuvers in and
records the best of the three maneuvers. The information generated is collected on a
microprocessor and then transmitted by a low power Bluetooth radio to the VitalFlo App
(password protected) on the user's iPhone. The user is alerted, by the App, if their
expiratory effort is inadequate (such as early termination of exhalation) and is provided
coaching for proper technique. The data is then transmitted to a HIPAA-compliant cloud
database. Participants will receive a survey after each time they measure lung function to
gather information about any asthma symptoms they are experiencing. Investigators will ask
that they use the spirometer prior to using albuterol for symptoms if possible. VitalFlo will
also track, via cloud databases, outdoor temperature, humidity, air quality, and pollen
counts: all environmental factors that can influence asthma symptoms. Routine calibration is
not needed. The eventual goal of home spirometer use is to identify drops in lung function
preceding asthma symptoms to allow persons with asthma to intervene with rescue medications
early in hopes of preventing progression to a more serious exacerbation of asthma ("red
zone") requiring healthcare utilization, such as emergency care or hospitalization.
This is a prospective single arm intervention study of 12-21 year olds with persistent
asthma. Participants will be given the home spirometer after receiving instruction on proper
use of the device. The participants will also receive an iPhone 5S (without SIM card) loaded
with the VitalFlo app. Participants will be asked to use the spirometer at least twice daily
(in the morning between 6am and 10am and in the evening between 6am and 10pm) and whenever
rescue medication (albuterol) is administered or the participant feels symptoms of asthma
(such as cough, wheezing, or shortness of breath) in order to document lung function.
Pulmonary function testing is known to show diurnal variability. Investigators will use the
morning and evening measurements to calculate the mean FEV1 for the day. After performing the
spirometry maneuver, the user will be prompted to answer questions about their asthma
symptoms. The lung function measurements and responses to the questions will be transmitted
to a cloud-based HIPAA-compliant database and will be available for the investigators to
download. Changes in lung function will be matched to subject-reported asthma symptoms and/or
albuterol use.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|